WHAT IS CLAIMED IS

1. A method of inhibiting angiogenesis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula (I)



(I),

or a therapeutically salt thereof, wherein

R^1, R^2, R^3, and R^4 are independently selected from the group consisting of hydrogen, alkoxy, alkoxycarbonylalkyl, alkyl, amino, aryl, arylalkyl, cyano, cyanoalkyl, cycloalkyl, (cycloalkyl)alkyl, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkyl, heterocycle, (heterocycle)alkyl, hydroxy, hydroxyalkyl, and nitroalkyl; and

R^5 and R^6 are independently selected from the group consisting of hydrogen, alkoxyalkyl, alkyl, alkynyl, alkylsulfanylalkyl, aminoalkyl, cyanoalkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, heteroarylalkyl, and (heterocycle)alkyl.

2. The method of claim 1 wherein R^4 is hydrogen.

3. The method of claim 2 wherein
R^1 and R^2 are hydrogen; and
R^3 is other than hydrogen.

4. The method of claim 3 wherein the compound of formula (I) is selected from the group consisting of
N-ethyl-5-methylnicotinamide;
N,N-diethyl-5-(2-methylphenyl)nicotinamide;
methyl 4-{5-[(diethylamino)carbonyl]-3-pyridinyl}benzoate;
5-(3-aminophenyl)-N,N-diethylnicotinamide;
N,N-diethyl-5-(2-methoxyphenyl)nicotinamide;
N,N-diethyl-5-(4-methoxyphenyl)nicotinamide;
N,N-diethyl-5-(3-fluorophenyl)nicotinamide;
N,N-diethyl-5-(4-fluorophenyl)nicotinamide;
5-(3-chlorophenyl)-N,N-diethylnicotinamide;
5-(2-bromophenyl)-N,N-diethylnicotinamide;
5-(3-bromophenyl)-N,N-diethylnicotinamide;

5-(3-cyanophenyl)-N,N-diethylnicotinamide;
5-(4-acetylphenyl)-N,N-diethylnicotinamide;
5-(2,5-dimethylphenyl)-N,N-diethylnicotinamide;
5-(3,4-dimethylphenyl)-N,N-diethylnicotinamide;
5-(3,5-dimethylphenyl)-N,N-diethylnicotinamide;
5-(3-ethoxyphenyl)-N,N-diethylnicotinamide;
5-(2,4-dimethoxyphenyl)-N,N-diethylnicotinamide;
5-(2,5-dimethoxyphenyl)-N,N-diethylnicotinamide;
5-(3,4-dimethoxyphenyl)-N,N-diethylnicotinamide;
5-[3-(acetylamino)phenyl]-N,N-diethylnicotinamide;
N,N-diethyl-5-(3,4,5-trimethoxyphenyl)nicotinamide;
N,N-diethyl-3,4'-bipyridine-5-carboxamide; and
N,N-diethyl-5-(3-furyl)nicotinamide.

5. The method of claim 2 wherein
R^1 and R^3 are hydrogen; and
R^2 is other than hydrogen.

6. The method of claim 5 wherein R^5 and R^6 are alkyl.

7. The method of claim 6 wherein the compound of formula (I) is selected from the group consisting of
N,N-diethyl-6-methylnicotinamide;
N,N-dimethyl-6-(1H-pyrazol-1-yl)nicotinamide;
N-butyl-N,6-dimethylnicotinamide;
N-isobutyl-N,6-dimethylnicotinamide;
N,6-dimethyl-N-pentylnicotinamide;
N,6-dimethyl-N-(3-methylbutyl)nicotinamide;
N-butyl-N-isopropyl-6-methylnicotinamide;
6-methyl-N,N-dipropylnicotinamide;
N-isopropyl-6-methyl-N-propylnicotinamide;
N-butyl-6-methyl-N-propylnicotinamide;
N-isopropyl-N,6-dimethylnicotinamide;
N,N-dibutyl-6-methylnicotinamide;
6-(4-aminophenyl)-N,N-diethylnicotinamide;
6-(3-acetylphenyl)-N,N-diethylnicotinamide;
6-[3-(acetylamino)phenyl]-N,N-diethylnicotinamide;

6-(3,5-dichlorophenyl)-N,N-diethylnicotinamide;
N,N-diethyl-6-(2-thienyl)nicotinamide;
6-bromo-N,N-diethylnicotinamide;
6-sec-butyl-N,N-diethylnicotinamide;
N,N-diethyl-6-(1-ethylpropyl)nicotinamide;
N,N-diethyl-6-hexylnicotinamide;
N,N-diethyl-6-(2-ethylbutyl)nicotinamide;
N,N-diethyl-6-(1-methylpentyl)nicotinamide;
N,N-diethyl-6-(1-ethylbutyl)nicotinamide;
6-(cyclohexylmethyl)-N,N-diethylnicotinamide;
6-(6-cyanohexyl)-N,N-diethylnicotinamide;
N,N-diethyl-6-(4-fluorobenzyl)nicotinamide;
methyl (3S)-3-{5-[(diethylamino)carbonyl]-2-pyridinyl}butanoate;
6-[(1S,2R,4R)-bicyclo[2.2.1]hept-2-yl]-N,N-diethylnicotinamide;
6-cyclohexyl-N,N-diethylnicotinamide;
6-(diethylamino)-N,N-diethylnicotinamide;
N,N-diethyl-6-(2-methyl-1-pyrrolidinyl)nicotinamide; and
6-[3-(aminocarbonyl)-1-piperidinyl]-N,N-diethylnicotinamide.

8. The method of claim 5 wherein one of R^5 and R^6 is hydrogen and the other is alkyl.

9. The method of claim 8 wherein the compound of formula (I) is selected from the group consisting of
N-ethyl-6-methylnicotinamide;
6-methyl-N-propylnicotinamide;
N-isopropyl-6-methylnicotinamide;
N-(sec-butyl)-6-methylnicotinamide;
N-isobutyl-6-methylnicotinamide;
N-(tert-butyl)-6-methylnicotinamide;
6-methyl-N-pentylnicotinamide;
6-methyl-N-(1-methylbutyl)nicotinamide;
6-methyl-N-(2-methylbutyl)nicotinamide;
6-methyl-N-(3-methylbutyl)nicotinamide;
6-methyl-N-neopentylnicotinamide; and
N-(3,3-dimethylbutyl)-6-methylnicotinamide.

10. The method of claim 5 wherein one of R^5 and R^6 is selected from the group consisting of hydrogen and alkyl and the other is selected from the group consisting of cycloalkyl and (cycloalkyl)alkyl.

11. The method of claim 10 wherein the compound of formula (I) is selected from the group consisting of
N-cyclohexyl-N,6-dimethylnicotinamide;
N-cyclopropyl-6-methylnicotinamide;
N-(cyclopropylmethyl)-6-methylnicotinamide;
N-cyclobutyl-6-methylnicotinamide;
N-cyclopentyl-6-methylnicotinamide;
N-(cyclopentylmethyl)-6-methylnicotinamide;
N-cyclohexyl-6-methylnicotinamide;
6-methyl-N-(2-methylcyclohexyl)nicotinamide;
6-methyl-N-(4-methylcyclohexyl)nicotinamide;
N-cycloheptyl-6-methylnicotinamide;
N-{[(1S,2R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl]methyl}-6-methylnicotinamide; and
N-(1-adamantylmethyl)-6-methylnicotinamide.

12. The method of claim 5 wherein one of R^5 and R^6 is selected from the group consisting of hydrogen and alkyl and the other is selected from the group consisting of hydrogen, alkoxyalkyl, cyanoalkyl, haloalkyl, and (heterocycle)alkyl.

13. The method of claim 12 wherein the compound of formula (I) is selected from the group consisting of
N-(cyanomethyl)-N,6-dimethylnicotinamide;
N-isopropyl-N-(2-methoxyethyl)-6-methylnicotinamide;
N-butyl-N-(cyanomethyl)-6-methylnicotinamide;
N,6-dimethyl-N-(tetrahydro-2-furanylmethyl)nicotinamide;
6-(2,2,2-trifluoroethoxy)nicotinamide;
6-methyl-N-(2,2,2-trifluoroethyl)nicotinamide;
N-(2-methoxyethyl)-6-methylnicotinamide;
N-(2-methoxy-1-methylethyl)-6-methylnicotinamide;
N-(2-ethoxyethyl)-6-methylnicotinamide;
N-(2-isopropoxyethyl)-6-methylnicotinamide;
6-methyl-N-(3-propoxypropyl)nicotinamide;
N-(3-methoxypropyl)-6-methylnicotinamide;

6-methyl-N-[(2S)-tetrahydro-2-furanylmethyl]nicotinamide;
6-methyl-N-[(2R)-tetrahydro-2-furanylmethyl]nicotinamide;
6-methyl-N-(tetrahydro-3-furanylmethyl)nicotinamide; and
N-(cyanomethyl)-6-methylnicotinamide.

14. The method of claim 5 wherein one of R^5 and R^6 is alkyl and the other is aminoalkyl.

15. The method of claim 14 wherein the compound of formula (I) is selected from the group consisting of
N-[2-(dimethylamino)ethyl]-N,6-dimethylnicotinamide;
N-[2-(dimethylamino)ethyl]-N-ethyl-6-methylnicotinamide;
N-[3-(dimethylamino)propyl]-N,6-dimethylnicotinamide; and
N-[2-(diethylamino)ethyl]-N,6-dimethylnicotinamide.

16. The method of claim 2 wherein
R^1 is as defined in claim 1; and
R^2 and R^3 are hydrogen.

17. The method of claim 16 wherein the compound of formula (I) is selected from the group consisting of
N-ethyl-2-methylnicotinamide; and
N,N-diethylnicotinamide.

18. The method of claim 2 wherein
R^1 and R^2 are other than hydrogen; and
R^3 is hydrogen.

19. The method of claim 18 wherein one of R^5 and R^6 is alkyl and the other is selected from the group consisting of hydrogen and alkyl.

20. The method of claim 19 wherein the compound of formula (I) is selected from the group consisting of
2-chloro-N-ethyl-N-isopropyl-6-methylnicotinamide;
2-chloro-N,N,6-trimethylnicotinamide;
N,N-diethyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N-isopropyl-N,2-dimethyl-6-(trifluoromethyl)nicotinamide;
N-butyl-N,2-dimethyl-6-(trifluoromethyl)nicotinamide;

N-isobutyl-N,2-dimethyl-6-(trifluoromethyl)nicotinamide;
N-ethyl-2-methyl-N-propyl-6-(trifluoromethyl)nicotinamide;
N-butyl-N-isopropyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N-isopropyl-2-methyl-N-propyl-6-(trifluoromethyl)nicotinamide;
N-butyl-2-methyl-N-propyl-6-(trifluoromethyl)nicotinamide;
N,N-dibutyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N,N-diisobutyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N-(sec-butyl)-2-chloro-6-methylnicotinamide;
2-chloro-6-methyl-N-pentylnicotinamide;
2-chloro-6-methyl-N-(2-methylbutyl)nicotinamide;
N-ethyl-2-methyl-6-(trifluoromethyl)nicotinamide;
2-methyl-N-propyl-6-(trifluoromethyl)nicotinamide;
N-isopropyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N-butyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N-(sec-butyl)-2-methyl-6-(trifluoromethyl)nicotinamide;
N-isobutyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N-(tert-butyl)-2-methyl-6-(trifluoromethyl)nicotinamide;
2-methyl-N-pentyl-6-(trifluoromethyl)nicotinamide;
2-methyl-N-(1-methylbutyl)-6-(trifluoromethyl)nicotinamide;
2-methyl-N-(2-methylbutyl)-6-(trifluoromethyl)nicotinamide;
2-methyl-N-(3-methylbutyl)-6-(trifluoromethyl)nicotinamide;
N-(1,1-dimethylpropyl)-2-methyl-6-(trifluoromethyl)nicotinamide;
N-(1-ethylpropyl)-2-methyl-6-(trifluoromethyl)nicotinamide;
N-hexyl-2-methyl-6-(trifluoromethyl)nicotinamide; and
N-(3,3-dimethylbutyl)-2-methyl-6-(trifluoromethyl)nicotinamide.

21. The method of claim 18 wherein one of R^5 and R^6 is selected from the group consisting of hydrogen and alkyl and the other is selected from the group consisting of alkoxyalkyl, cyanoalkyl and cycloalkyl.

22. The method of claim 21 wherein the compound of formula (I) is selected from the group consisting of
2-chloro-N-cyclohexyl-N-ethyl-6-methylnicotinamide;
N-cyclohexyl-N,2-dimethyl-6-(trifluoromethyl)nicotinamide;
N-cyclohexyl-N-ethyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N-(cyanomethyl)-N,2-dimethyl-6-(trifluoromethyl)nicotinamide;
N-(2-cyanoethyl)-N,2-dimethyl-6-(trifluoromethyl)nicotinamide;

N-butyl-N-(cyanomethyl)-2-methyl-6-(trifluoromethyl)nicotinamide;
2-chloro-N-(2-ethoxyethyl)-6-methylnicotinamide;
2-chloro-6-methyl-N-(3-propoxypropyl)nicotinamide;
2-chloro-N-(3-methoxypropyl)-6-methylnicotinamide;
2-chloro-N-(cyanomethyl)-6-methylnicotinamide;
2-chloro-N-cyclopropyl-6-methylnicotinamide;
2-chloro-N-cyclohexyl-6-methylnicotinamide;
2-chloro-6-methyl-N-(3-methylcyclohexyl)nicotinamide;
N-(4-tert-butylcyclohexyl)-2-chloro-6-methylnicotinamide;
2-chloro-N-cycloheptyl-6-methylnicotinamide;
N-(2-methoxy-1-methylethyl)-2-methyl-6-(trifluoromethyl)nicotinamide;
N-(2-isopropoxyethyl)-2-methyl-6-(trifluoromethyl)nicotinamide;
2-methyl-N-(3-propoxypropyl)-6-(trifluoromethyl)nicotinamide;
N-(3-methoxypropyl)-2-methyl-6-(trifluoromethyl)nicotinamide;
N-(cyanomethyl)-2-methyl-6-(trifluoromethyl)nicotinamide;
N-cyclobutyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N-cyclopentyl-2-methyl-6-(trifluoromethyl)nicotinamide;
N-cyclohexyl-2-methyl-6-(trifluoromethyl)nicotinamide;
2-methyl-N-(2-methylcyclohexyl)-6-(trifluoromethyl)nicotinamide;
2-methyl-N-(4-methylcyclohexyl)-6-(trifluoromethyl)nicotinamide; and
N-2-adamantyl-2-methyl-6-(trifluoromethyl)nicotinamide.

23. The method of claim 18 wherein one of R^5 and R^6 is selected from the group consisting of hydrogen and alkyl and the other is selected from the group consisting of alkylsulfanylalkyl, alkynyl, (cycloalkyl)alkyl, and (heterocycle)alkyl.

24. The method of claim 23 wherein the compound of formula (I) is selected from the group consisting of
N-(1,3-dioxolan-2-ylmethyl)-N,2-dimethyl-6-(trifluoromethyl)nicotinamide;
N,2-dimethyl-N-2-propynyl-6-(trifluoromethyl)nicotinamide;
2-chloro-6-methyl-N-[(2S)-tetrahydro-2-furanylmethyl]nicotinamide;
2-chloro-6-methyl-N-[(2R)-tetrahydro-2-furanylmethyl]nicotinamide;
2-chloro-N-(cyclopropylmethyl)-6-methylnicotinamide;
2-chloro-N-(cyclohexylmethyl)-6-methylnicotinamide;
2-methyl-N-[2-(methylsulfanyl)ethyl]-6-(trifluoromethyl)nicotinamide;
2-methyl-N-[(2S)-tetrahydro-2-furanylmethyl]-6-(trifluoromethyl)nicotinamide;
2-methyl-N-[(2R)-tetrahydro-2-furanylmethyl]-6-(trifluoromethyl)nicotinamide;

2-methyl-N-2-propynyl-6-(trifluoromethyl)nicotinamide;
N-(cyclopropylmethyl)-2-methyl-6-(trifluoromethyl)nicotinamide; and
N-(1-adamantylmethyl)-2-methyl-6-(trifluoromethyl)nicotinamide.

25. A method of inhibiting angiogenesis comprising administering to a human in need of such treatment a therapeutically effective amount of a compound of claim 1 or a therapeutically acceptable salt thereof.

26. A method of treating cancer comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 or a therapeutically acceptable salt thereof.

27. A method of treating cancer comprising administering to a human in need of such treatment a therapeutically effective amount of a compound of claim 1 or a therapeutically acceptable salt thereof.

28. A compound of formula (II)



(II),

or a therapeutically acceptable salt thereof, wherein

R^1 and R^4 are independently selected from the group consisting of hydrogen, alkoxy, alkoxycarbonylalkyl, alkyl, arylalkyl, cyano, cyanoalkyl, cycloalkyl, (cycloalkyl)alkyl, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkyl, heterocycle, (heterocycle)alkyl, hydroxy, hydroxyalkyl, and nitroalkyl;

R^2 and R^3 are independently selected from the group consisting of hydrogen, alkoxy, alkoxycarbonylalkyl, alkyl, aryl, arylalkyl, cyano, cyanoalkyl, cycloalkyl, (cycloalkyl)alkyl, halo, haloalkoxy, haloalkyl, heteroaryl, heteroarylalkyl, heterocycle, (heterocycle)alkyl, hydroxy, and hydroxyalkyl; provided that at least one of R^1, R^2, R^3, and R^4 is other than hydrogen; and

one of R^5 and R^6 is alkyl and the other is selected from the group consisting of alkoxyalkyl and dialkylaminoalkyl.

29. The compound of claim 28 selected from the group consisting of
N-isopropyl-N-(2-methoxyethyl)-6-methylnicotinamide;

N-[2-(dimethylamino)ethyl]-N,6-dimethylnicotinamide;
N-[2-(dimethylamino)ethyl]-N-ethyl-6-methylnicotinamide;
N-[3-(dimethylamino)propyl]-N,6-dimethylnicotinamide; and
N-[2-(diethylamino)ethyl]-N,6-dimethylnicotinamide.

30. A pharmaceutical composition comprising a compound of claim 28 or a therapeutically acceptable salt thereof in combination with a therapeutically acceptable carrier or a therapeutically acceptable salt thereof.

29. A method of inhibiting angiogenesis comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 28 or a therapeutically acceptable salt thereof.

30. A method of inhibiting angiogenesis comprising administering to a human in need of such treatment a therapeutically effective amount of a compound of claim 28 or a therapeutically acceptable salt thereof.

31. A method of treating cancer comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 28 or a therapeutically acceptable salt thereof.

32. A method of treating cancer comprising administering to a human in need of such treatment a therapeutically effective amount of a compound of claim 28 or a therapeutically acceptable salt thereof.